Drug Profile
Research programme: RNA interference-based metabolic disorders therapeutics - Adhera Therapeutics
Alternative Names: MDR-04227; MDR-09885Latest Information Update: 17 Apr 2019
Price :
$50
*
At a glance
- Originator MDRNA
- Developer Marina Biotech
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia